Back

Atrial fibrillation and risk of pulmonary arterial hypertension. Swedisk nationwide registry study

26 August 2018 (15:50 - 16:40)
Organised by:
Congress Presentation Part of: Atrial fibrillation - General 2 Clinical ESC Premium Access ESC Congress 2018

About the speaker

Photo
Doctor Bjorn Hornestam

Sahlgrenska Academy, Gothenburg (Sweden)

6 More presentations in this session

Presentation thumbnail
Four targeted therapies and less than four targeted therapies of underlying conditions against conventional therapy in atrial fibrillation - data from the RACE 3 study
Miss B. Nguyen (Groningen, NL)
Abstract Slides
Presentation thumbnail
SGLT 2 inhibitor suppresses atrial fibrillation in the canine model of atrial fibrillation.
Doctor R. Nishinarita (Tokyo, JP)
Abstract Slides
Presentation thumbnail
Association of left atrial size with ischemic and bleeding risk scores in patients with non-valvular atrial fibrillation
Doctor L. Enriquez Rodriguez (Soria, ES)
Abstract Slides
Presentation thumbnail
How could non-vitamin k antagonist oral anticoagulants change clinical practice for stroke prevention and improve outcomes in patients with newly-diagnosed atrial fibrillation?
Doctor T. Chao (Taipei, TW)
Abstract
Presentation thumbnail
High body mass index and outcomes of dual antithrombotic therapy with dabigatran and a P2Y12 inhibitor in patients with atrial fibrillation undergoing PCI: Results from RE-DUAL PCI
Doctor R. De Caterina (Pisa, IT)
Abstract Slides

Access the full session

Session thumbnail
Atrial fibrillation - General 2

The Event

Event poster

ESC Congress 2018

26 August 2018 15:50 CET
You may be interested in
thumbnail
Congress Session
EHRA Myths - Device-detected atrial fibrillation
thumbnail
Congress Session
Stroke prevention in clinical and subclinical atrial fibrillation
thumbnail
Congress Session
Treatment strategies for atrial fibrillation in heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources